Studies

In this study, the researchers investigated the use of a topical gel containing 0.75% metronidazole for treating seborrheic dermatitis, a skin condition. They compared it to a placebo (inactive gel) in two groups of 40 patients.

After 8 weeks, 33 patients completed the study. However, the results showed no significant difference in the severity of seborrheic dermatitis between the group using the metronidazole gel and the group using the placebo.

Additionally, some patients using metronidazole experienced side effects, leading the researchers to conclude that the 0.75% metronidazole gel was not more effective than the placebo for treating seborrheic dermatitis in this study.

This study aimed to test the effectiveness of 1% metronidazole gel in treating seborrheic dermatitis.

In a double-blind clinical trial with 56 patients, half used the metronidazole gel, and the other half used a placebo for 8 weeks.

Results showed a significant reduction in severity scores for the metronidazole group compared to the placebo group at the second, fourth, sixth, and eighth weeks of treatment.

In conclusion, the study found that 1% metronidazole gel is an effective treatment for facial seborrheic dermatitis

In a study involving 60 patients with facial seborrheic dermatitis, researchers compared the effectiveness and safety of metronidazole 0.75% gel with ketoconazole 2% cream.

Both treatments showed similar improvement in clinical severity scores, with a 63.4% decrease for ketoconazole and 54.4% for metronidazole. Patients in both groups reported significant or moderate global improvement, and there was no significant difference in side effects between the two treatments.

The study suggests that metronidazole 0.75% gel is as effective and safe as ketoconazole 2% cream for treating facial seborrheic dermatitis.

In this study, researchers tested the effectiveness of metronidazole 0.75% gel in treating mild to moderate seborrhoeic dermatitis.

They enrolled 67 patients and randomly assigned them to receive either the metronidazole gel or a placebo for four weeks. Patients were assessed weekly during treatment and twice in the following four weeks.

Both groups showed significant improvement in symptoms like redness, scales, bumps, and itching during treatment, but there was no notable difference in effectiveness between the metronidazole gel and the placebo. After treatment, all patients experienced a rapid return of symptoms to baseline levels.

The conclusion is that while metronidazole 0.75% gel is well tolerated, it’s not more effective than a placebo in treating seborrhoeic dermatitis, and symptoms quickly return after stopping the treatment.

In this study, researchers compared three topical treatments for facial seborrhoeic dermatitis: pimecrolimus cream 1%, methylprednisolone aceponate 0.1% cream, and metronidazole 0.75% gel. They conducted an 8-week trial with 64 patients, evaluating the severity of the condition based on erythema, scaling, and pruritus.

Results showed that all treatments were effective, but pimecrolimus was more effective than metronidazole and methylprednisolone. Additionally, metronidazole had more side effects compared to pimecrolimus. The study suggests that pimecrolimus could be a good therapeutic option for cases of seborrhoeic dermatitis that don’t respond well to methylprednisolone aceponate.

This study explored the influence of nickel and parasitic infections on psoriasis using gene expression data. Surprisingly, the research identified metronidazole as a potential treatment. Nickel was found to upregulate certain genes associated with psoriasis and downregulate others. This impact was observed in pathways related to immune response, defense, cell cycle, and metabolism. The study suggests that recognizing abnormal nickel levels could enhance our understanding of psoriasis, with metronidazole showing promise in alleviating skin inflammation based on the findings.